Documente Academic
Documente Profesional
Documente Cultură
WHO
The Expert Committee on the Diagn.and Classif. of Diabetes Mellitus (from the ADA) Diab.Care 2004; Vol 27, suppl 1 S5 to S10
300
250 200 150 100 50
1995
2000
2010
2025
International Diabetes Federation. Diabetes Atlas Executive Summary. Second Edition. IDF publ. 2003; 7-14
10
15
50
55
Criterii de diagnostic
DIABETUL ZAHARAT
TTGO- interpretare: glicemie bazal < 100 mg/dl, la 2h <140 mg/dl NORMAL 100-126 <140 IFG 100-126 140-199 IFG+IGT i/sau > 126 > 200 DIABET ZAHARAT
IFG = impaired fasting glucose IGT = impaired glucose tolerance
Persoane cu afectare coronarian preexistent, afectare cerebrovascular, boala arterial periferic sau HTA
Persoane cu dislipidemie Femei cu istoric de diabet gestaional sau macrosomie
>9.9 mmol/L
>180 mg/dl
135
puin probabil diabetic
154
cel mai probabil diabetic
5.6 la 7 mmol/L
100-125,9 mg/dl
>7 mmol/L
>126 mg/dl
pacient cu diabet
>11.1 mmol/L
>200 mg/dl
IGT
pacient cu diabet
Cardiovascular disease
Boli cardiovasculare (cauz de deces pentru 80% dintre diabetici)4
Diabetic neuropathy
Nefropatie diabetic 2 insuficien renal sever Neuropatie diabetic, Piciorul diabetic amputaii5
DS, et al. Diabetes Care 2003; 26(Suppl. 1):S99S102. 2Molitch ME, et al. Diabetes Care 2003; 26(Suppl.1):S94S98. WB, et al. Am Heart J 1990; 120:672676. 4Gray RP & Yudkin JS. In Textbook of Diabetes 1997.5Mayfield JA, et al. Diabetes Care 2003; 26(Suppl. 1):S78S79.
1Fong
3Kannel
Fr un IM anterior
Cu un IM Cardiovascular disease anterior
Risc dublu de IM
Diabetic neuropathy
diabetici
Johnson JA, Majumdar SR,Simpson SH, Toth El.Decreased mortality. Diabetes Care.2002;25:2244-2248
DIABETUL ZAHARAT
ECHIVALENT DE RISC CARDIOVASCULAR
Boal cardiovascular
Boal coronarian
6684
3042
1%
AVC
5962
3748
Selvin E, Marinopoulos S, Berkenblit G.et al,Meta-analysis:glycosilated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern.Med.2004;141:421-31
inte terapeutice
HbA1c < 6,5%
glicemie plasmatic < 110mg/dl (6 mmol/l) preprandial glicemie la 1-2 ore dup mas < 145mg/dl (< 8mmol/l ) LDL-colesterol HDL-colesterol Trigliceride < 100 mg/dl > 40 mg/dl < 150 mg/dl
IDF 2005
Diet
Exerciii fizice
Nu
HbA1c 7%
Da
Nu
HbA1c7%
Da
Nu
HbA1c7%
Da
Nu
HbA1c7%
Da
Insulinoterapie intensiva
Asociere glitazone
Asociere sulfoniluree
Nu
HbA1c7%
Da
* *
6.0
4.0
8:00
12:00
3:00
8:00
Guillausseau PJ, Greb WH ,24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily;Diabetes Metab. 2001, 27(2)
P. Drouin -Diamicron MR study group; Long term treatment of type 2 diabetic patients with a new once daily gliclazide formulation, Diamicron MR: a double blind randomized comparison with Diamicron 80mg. J Diabetes Complications, 2000; 14: 185-191
Mannucci E.et al;42nd Annual EASD Annual Meeting; September 14-16 2006, Copenhagen, Denmark and Malmo, Sweden. OP 13-0078
Scherntaner G, Grimaldi A, Di Mario U. et al. GUIDE study: double blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004; 34:535-542
cu metformin
protecie cardiovascular optim tolerabilitate excelent